Bio-Path Investor Relations Material
Latest events
Q3 2024
Bio-Path
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Bio-Path Holdings Inc
Access all reports
Bio-Path Holdings Inc. is a biotechnology company focused on the development of RNAi-based therapies for cancer treatment. The company uses its proprietary DNAbilize® platform to design lipid-delivered RNAi therapeutics that target specific proteins involved in cancer cell survival and proliferation. Bio-Path’s lead programs focus on treating hematologic cancers such as leukemia and lymphoma. The company’s approach aims to provide innovative treatment options for patients with unmet medical needs in oncology. The company is headquartered in Bellaire, Texas, USA, and its shares are listed on the NASDAQ.
Latest articles
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
BPTH
Country
🇺🇸 United States